Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-412: pembrolizumab with chemoradiotherapy versus placebo with chemoradiotherapy in locally advanced head and neck squamous cell carcinoma
MOH_2017-02-22_000133Phase 3Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Feb 2017
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of pembrolizumab in head and neck squamous cell carcinoma (HNSCC) (2 arms), sponsored by Merck & Co. Started Feb 2017; status: active, not recruiting.
02
Drugs
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2017-02-22_000133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-02-22_000133.